Table 18: Treatment Effects for the Primary Endpoints* and their Components* in the DECLARE Trial Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial Chronic Kidney Disease The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dosage of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
Impact of in vitro heavy metal exposure on pancreatic -cell function
More than four billion peopleabout 50 percent of the worlds populationare estimated to be impacted by obesity or will be overweight by 2035
Emerging research involving two distinctive models, including zip10 mutant zebrafish as well as the hematopoietic Zip10-deficient mice, has made significant strides in our understanding of hematopoiesis
Two of the three sequences are nearly identical and therefore were considered as the products of the same gene
